Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155020 | 0.86 | AVPR1A (0.51) | AVPR1AMAPK1TSHRALOX15 | |
| SCHEMBL6155641 | 0.84 | AVPR1A (0.52) | AVPR1ATSHR | |
| SCHEMBL6153716 | 0.79 | KDM1A (0.50) | AVPR1AKDM1AHDAC1HDAC8HDAC6 | |
| SCHEMBL6154922 | 0.79 | AVPR1A (0.51) | AVPR1AMAPK1KDM1ATSHRPDK2 | |
| SCHEMBL9965972 | 0.78 | AVPR1A (0.48) | AVPR1AMAPK1TSHR | |
| SCHEMBL7672299 | 0.78 | OPRD1 (0.46) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL21940364 | 0.77 | HDAC1 (0.49) | AVPR1AMAPK1KDM1ATSHRALOX15 | |
| SCHEMBL2109651 | 0.76 | RBP4 (0.51) | MAPK1KDM1ATSHRALOX15HDAC1 | |
| SCHEMBL23902054 | 0.75 | MAPK1 (0.51) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL29609790 | 0.75 | MAPK1 (0.51) | MAPK1KDM1ATSHRALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209262-A1 | Process for producing optically active sulfoxide | SANKYO COMPANY, LIMITED (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1557420-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE | Sankyo Company, Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-0776893-B1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO CO (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209262-A1 | Process for producing optically active sulfoxide | TST, TMT1A, PPOX | AVPR1A 3530/4885MAPK1 2424/4885KDM1A 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.